Cambrian Biopharma has backed a round that will go toward further developing Vita’s lead candidate, VTA-110, for muscular dystrophy treatments.

Amadeus Capital Partners has bought a stake in the University of Oxford spinout through a secondary transaction, valuing it at around $2.4bn.

The Johns Hopkins University spinout’s latest funding will go toward further developing its lead candidate, VTA-110, for muscular dystrophy treatments.

WuXi AppTec and New World Development-backed Adagene has raised close to $140m in its initial public offering after having secured $155m in equity financing.

The Telefónica-backed digital mental health services provider has secured an extension to close its series A round at $36m.

Optum has co-led a $26 round for the health network provider, whose existing shareholders include iCarbonX.

Ascletis Pharma has returned for an $80m round that will fund the further clinical development of a potential treatment for non-alcoholic steatohepatitis symptoms.

The $9.5m investment vehicle will be run by Opt unit Bonds Investment Group for up to 13 years, targeting local entrepreneurs.

Caltech spinout Talis Biomedical has raised more than $220m in an initial public offering on the Nasdaq Global Market.

Equip has raised $17m in total to make eating disorder treatment accessible.